Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: tada f. Hepatol Res. 2023 Feb;53(2):104-115. doi: 10.1111/hepr.13843. Epub 2022 Nov 6. Hepatol Res. 2023. PMID: 36149726
AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.
Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Ochi H, Hiraoka A, Yagi S, Yukimoto A, Hirooka M, Abe M, Hiasa Y. Watanabe T, et al. Among authors: tada f. BMC Cancer. 2021 Jun 14;21(1):699. doi: 10.1186/s12885-021-08401-7. BMC Cancer. 2021. PMID: 34126947 Free PMC article.
Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test.
Hiraoka A, Nakai M, Hara N, Hanai T, Namisaki T, Miyaaki H, Nakahara T, Hiramatsu A, Ohama H, Tada F, Takahashi H, Aikata H, Eguchi Y, Hiasa Y, Yoshiji H. Hiraoka A, et al. Among authors: tada f. Hepatol Res. 2023 Jan;53(1):43-50. doi: 10.1111/hepr.13835. Epub 2022 Sep 15. Hepatol Res. 2023. PMID: 36063444
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: tada f, tada t. Oncology. 2022;100(12):645-654. doi: 10.1159/000526521. Epub 2022 Sep 14. Oncology. 2022. PMID: 36103846
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: tada f. Hepatol Res. 2023 Feb;53(2):116-126. doi: 10.1111/hepr.13852. Epub 2022 Nov 16. Hepatol Res. 2023. PMID: 36316794
Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment.
Ohama H, Hiraoka A, Tada F, Kato K, Fukunishi Y, Yanagihara E, Kato M, Saneto H, Izumoto H, Ueki H, Yoshino T, Kitahata S, Kawamura T, Kuroda T, Suga Y, Miyata H, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Ohama H, et al. Among authors: tada f. Cancers (Basel). 2022 Nov 10;14(22):5524. doi: 10.3390/cancers14225524. Cancers (Basel). 2022. PMID: 36428616 Free PMC article.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, Toyoda H, Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Matono T, Kaibori M, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: tada f. Oncology. 2023;101(4):270-282. doi: 10.1159/000527676. Epub 2022 Dec 1. Oncology. 2023. PMID: 36455517
88 results